DrugPatentWatch Database Preview
Patent: 10,258,619
» See Plans and Pricing
Summary for Patent: 10,258,619
| Title: | Combination therapy with glutaminase inhibitors and immuno-oncology agents |
| Abstract: | The invention relates to methods of treating cancer, myeloproliferative diseases, or immunological or neurological diseases with a combination of a glutaminase inhibitor and an immuno-oncology therapeutic agent, such as an inhibitor of arginase, CTLA-4, indoleamine 2,3-dioxygenase, and/or PD-1/PD-L1. |
| Inventor(s): | Molineaux; Susan M. (San Francisco, CA), Gross; Matthew I. (San Francisco, CA), Bromley; Susan D. (San Francisco, CA), Parlati; Francesco (San Francisco, CA), Bennett; Mark K. (Moraga, CA) |
| Assignee: | Calithera Biosciences, Inc. (South San Francisco, CA) |
| Application Number: | 15/284,865 |
| Patent Claims: | see list of patent claims |
Details for Patent 10,258,619
| Applicant | Tradename | Biologic Ingredient | Dosage Form | BLA | Number | Approval Date | Patent No. | Assignee | Estimated Patent Expiration | Status | Orphan | Source |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Genentech | RITUXAN | rituximab | SOLUTION;INTRAVENOUS | 103705 | 001 | 1997-11-26 | Start Trial | Calithera Biosciences, Inc. (South San Francisco, CA) | 2035-10-05 | RX | search | |
| Genentech | RITUXAN | rituximab | SOLUTION;INTRAVENOUS | 103705 | 002 | 1997-11-26 | Start Trial | Calithera Biosciences, Inc. (South San Francisco, CA) | 2035-10-05 | RX | search | |
| Genzyme | CAMPATH | alemtuzumab | VIAL; INTRAVENOUS | 103948 | 001 | 2001-05-07 | Start Trial | Calithera Biosciences, Inc. (South San Francisco, CA) | 2035-10-05 | RX | Orphan | search |
| Genzyme | CAMPATH | alemtuzumab | VIAL; INTRAVENOUS | 103948 | 002 | 2001-05-07 | Start Trial | Calithera Biosciences, Inc. (South San Francisco, CA) | 2035-10-05 | RX | Orphan | search |
| Genzyme | LEMTRADA | alemtuzumab | INJECTABLE;INJECTION | 103948 | 003 | 2001-05-07 | Start Trial | Calithera Biosciences, Inc. (South San Francisco, CA) | 2035-10-05 | RX | Orphan | search |
| Novartis | ARZERRA | ofatumumab | INJECTABLE; INJECTION | 125326 | 001 | 2009-10-26 | Start Trial | Calithera Biosciences, Inc. (South San Francisco, CA) | 2035-10-05 | RX | search | |
| Novartis | KESIMPTA | ofatumumab | SOLUTION;SUBCUTANEOUS | 125326 | 002 | 2009-10-26 | Start Trial | Calithera Biosciences, Inc. (South San Francisco, CA) | 2035-10-05 | RX | search | |
| >Applicant | >Tradename | >Biologic Ingredient | >Dosage Form | >BLA | >Number | >Approval Date | >Patent No. | >Assignee | >Estimated Patent Expiration | >Status | >Orphan | >Source |
